v3.21.1
Consolidated Statements of Operations - USD ($)
9 Months Ended 12 Months Ended
Dec. 31, 2020
Mar. 31, 2020
REVENUES    
Total revenues $ 2,849,561 $ 5,557,967
EXPENSES    
Cost of product sales 915,810 1,489,487
Cost of product sales-related party 1,724,338 2,488,542
General and administrative 7,105,337 1,510,068
Research and development 3,316,099 679,620
Research and development-related party 525,499
Sales and marketing 307,903 367,953
Impairment loss on construction in progress 1,376,000
Total expenses 14,745,487 7,061,169
LOSS FROM OPERATIONS (11,895,926) (1,503,202)
OTHER EXPENSE (INCOME), NET    
Change in fair value of warrant liabilities 8,310,100
Gain on loan extinguishment (451,345)
Interest expense, net 48,039 283,095
Other income, net (256,354) (2,785)
Total other expense, net 7,650,440 280,310
LOSS BEFORE PROVISION FOR INCOME TAXES (19,546,366) (1,783,512)
PROVISION FOR INCOME TAXES 4,000
NET LOSS $ (19,546,366) $ (1,787,512)
Net loss per common share, basic and diluted $ (1.12) $ (0.32)
Weighted-average number of shares outstanding, basic and diluted 17,431,714 5,602,214
Net Product Sales [Member]    
REVENUES    
Total revenues $ 1,209,186 $ 2,070,707
Net Product Sales-Related Party [Member]    
REVENUES    
Total revenues 1,640,375 3,402,260
Collaborative Research Revenue [Member]    
REVENUES    
Total revenues $ 85,000

Source